Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sönnerborg A[au]:

Search results

Items: 1 to 50 of 365

1.

Antiretroviral treatment for HIV infection: Swedish recommendations 2019.

Eriksen J, Carlander C, Albert J, Flamholc L, Gisslén M, Navér L, Svedhem V, Yilmaz A, Sönnerborg A.

Infect Dis (Lond). 2020 Jan 11:1-35. doi: 10.1080/23744235.2019.1707867. [Epub ahead of print]

PMID:
31928282
2.

MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors.

Aralaguppe SG, Ambikan AT, Ashokkumar M, Kumar MM, Hanna LE, Amogne W, Sönnerborg A, Neogi U.

Viruses. 2019 Aug 30;11(9). pii: E806. doi: 10.3390/v11090806.

3.

GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds.

Singh K, Gallazzi F, Hill KJ, Burke DH, Lange MJ, Quinn TP, Neogi U, Sönnerborg A.

Front Microbiol. 2019 Jun 20;10:1227. doi: 10.3389/fmicb.2019.01227. eCollection 2019.

4.

A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.

Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Marrone G, Grossmann S, Neogi U, Tegbaru B, Sönnerborg A.

BMC Infect Dis. 2019 Jul 1;19(1):569. doi: 10.1186/s12879-019-4196-8.

5.

HIV elite control is associated with reduced TRAILshort expression.

Paim AC, Cummins NW, Natesampillai S, Garcia-Rivera E, Kogan N, Neogi U, Sönnerborg A, Sperk M, Bren GD, Deeks S, Polley E, Badley AD.

AIDS. 2019 Sep 1;33(11):1757-1763. doi: 10.1097/QAD.0000000000002279.

6.

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase.

Singh K, Sarafianos SG, Sönnerborg A.

Pharmaceuticals (Basel). 2019 Apr 20;12(2). pii: E62. doi: 10.3390/ph12020062. Review.

7.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

8.

Challenges in modelling the proportion of undiagnosed HIV infections in Sweden.

Andersson E, Nakagawa F, van Sighem A, Axelsson M, Phillips AN, Sönnerborg A, Albert J.

Euro Surveill. 2019 Apr;24(14). doi: 10.2807/1560-7917.ES.2019.24.14.1800203.

9.

Microfluidic centrifugation assisted precipitation based DNA quantification.

Banerjee I, Aralaguppe SG, Lapins N, Zhang W, Kazemzadeh A, Sönnerborg A, Neogi U, Russom A.

Lab Chip. 2019 Apr 23;19(9):1657-1664. doi: 10.1039/c9lc00196d.

PMID:
30931470
10.

Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics.

Sarfo FS, Castelnuovo B, Fanti I, Feldt T, Incardona F, Kaiser R, Lwanga I, Marrone G, Sonnerborg A, Tufa TB, Zazzi M, De Luca A.

J Infect. 2019 May;78(5):402-408. doi: 10.1016/j.jinf.2019.03.003. Epub 2019 Mar 6.

PMID:
30849438
11.

HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness.

van Domselaar R, Njenda DT, Rao R, Sönnerborg A, Singh K, Neogi U.

J Virol. 2019 Apr 17;93(9). pii: e00077-19. doi: 10.1128/JVI.00077-19. Print 2019 May 1.

12.

Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models.

Santacatterina M, García-Pareja C, Bellocco R, Sönnerborg A, Ekström AM, Bottai M.

Stat Med. 2019 May 10;38(10):1891-1902. doi: 10.1002/sim.8080. Epub 2018 Dec 27.

PMID:
30592073
13.

Strain-specific effect on biphasic DNA binding by HIV-1 integrase.

Hill KJ, Rogers LC, Njenda DT, Burke DH, Sarafianos SG, Sönnerborg A, Neogi U, Singh K.

AIDS. 2019 Mar 1;33(3):588-592. doi: 10.1097/QAD.0000000000002078.

PMID:
30475264
14.

Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution.

Zhang W, Svensson Akusjärvi S, Sönnerborg A, Neogi U.

Front Microbiol. 2018 Oct 2;9:2358. doi: 10.3389/fmicb.2018.02358. eCollection 2018.

15.

The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.

Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR).

AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046.

PMID:
30325769
16.

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes.

Rogers L, Obasa AE, Jacobs GB, Sarafianos SG, Sönnerborg A, Neogi U, Singh K.

Front Microbiol. 2018 Aug 2;9:1754. doi: 10.3389/fmicb.2018.01754. eCollection 2018.

17.

Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Njenda DT, Aralaguppe SG, Singh K, Rao R, Sönnerborg A, Sarafianos SG, Neogi U.

J Antimicrob Chemother. 2018 Oct 1;73(10):2721-2728. doi: 10.1093/jac/dky256.

18.

Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia.

Telele NF, Kalu AW, Marrone G, Gebre-Selassie S, Fekade D, Tegbaru B, Sönnerborg A.

PLoS One. 2018 Jul 11;13(7):e0200505. doi: 10.1371/journal.pone.0200505. eCollection 2018.

19.

Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.

Kalu AW, Telele NF, Aralaguppe SG, Gebre-Selassie S, Fekade D, Marrone G, Sonnerborg A.

Curr HIV Res. 2018;16(2):113-120. doi: 10.2174/1570162X16666180515124836.

PMID:
29766813
20.

Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing.

Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Abdurahman S, Marrone G, Neogi U, Tegbaru B, Sönnerborg A.

Sci Rep. 2018 May 15;8(1):7556. doi: 10.1038/s41598-018-25888-6.

21.

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia.

Carlander C, Wagner P, van Beirs A, Yilmaz A, Elfgren K, Dillner J, Sönnerborg A, Sparén P.

AIDS. 2018 Jul 17;32(11):1475-1484. doi: 10.1097/QAD.0000000000001853.

PMID:
29746299
22.

Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

Buggert M, Nguyen S, McLane LM, Steblyanko M, Anikeeva N, Paquin-Proulx D, Del Rio Estrada PM, Ablanedo-Terrazas Y, Noyan K, Reuter MA, Demers K, Sandberg JK, Eller MA, Streeck H, Jansson M, Nowak P, Sönnerborg A, Canaday DH, Naji A, Wherry EJ, Robb ML, Deeks SG, Reyes-Teran G, Sykulev Y, Karlsson AC, Betts MR.

PLoS Pathog. 2018 Apr 13;14(4):e1006973. doi: 10.1371/journal.ppat.1006973. eCollection 2018 Apr.

23.

Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells.

Noyan K, Nguyen S, Betts MR, Sönnerborg A, Buggert M.

Front Immunol. 2018 Jan 22;9:19. doi: 10.3389/fimmu.2018.00019. eCollection 2018.

24.

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.

Sörstedt E, Carlander C, Flamholc L, Hejdeman B, Svedhem V, Sönnerborg A, Gisslén M, Yilmaz A.

Int J Antimicrob Agents. 2018 May;51(5):733-738. doi: 10.1016/j.ijantimicag.2018.01.009. Epub 2018 Jan 31.

PMID:
29371105
25.

Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden.

Andersson E, Nordquist A, Esbjörnsson J, Flamholc L, Gisslén M, Hejdeman B, Marrone G, Norrgren H, Svedhem V, Wendahl S, Albert J, Sönnerborg A.

AIDS. 2018 Apr 24;32(7):877-884. doi: 10.1097/QAD.0000000000001763.

PMID:
29369826
26.

Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017.

Navér L, Albert J, Carlander C, Flamholc L, Gisslén M, Karlström O, Svedhem-Johansson V, Sönnerborg A, Westling K, Yilmaz A, Pettersson K.

Infect Dis (Lond). 2018 Jul;50(7):495-506. doi: 10.1080/23744235.2018.1428825. Epub 2018 Jan 24. Review.

PMID:
29363407
27.

Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers.

Zhang W, Ambikan AT, Sperk M, van Domselaar R, Nowak P, Noyan K, Russom A, Sönnerborg A, Neogi U.

EBioMedicine. 2018 Jan;27:40-50. doi: 10.1016/j.ebiom.2017.11.031. Epub 2017 Dec 12.

28.

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, Hejdeman B, Sönnerborg A.

AIDS. 2018 Feb 20;32(4):469-476. doi: 10.1097/QAD.0000000000001726.

29.

Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.

Olson A, Bannert N, Sönnerborg A, de Mendoza C, Price M, Zangerle R, Chaix ML, Prins M, Kran AB, Gill J, Paraskevis D, Porter K; for CASCADE Collaboration in EuroCoord.

AIDS. 2018 Jan 14;32(2):161-169. doi: 10.1097/QAD.0000000000001689.

PMID:
29112061
30.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210.

31.

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.

McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, Gupta N, Gkrania-Klotsas E, Young EH, Bannert N, Del Amo J, Gill MJ, Gilmour J, Kellam P, Kelleher AD, Sönnerborg A, Zangerle R, Post FA, Fisher M, Haas DW, Walker BD, Porter K, Goldstein DB, Sandhu MS, de Bakker PIW, Fellay J.

J Infect Dis. 2017 Nov 27;216(9):1063-1069. doi: 10.1093/infdis/jix470. Erratum in: J Infect Dis. 2018 Jun 5;218(1):171.

32.

PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context.

Libin P, Vanden Eynden E, Incardona F, Nowé A, Bezenchek A; EucoHIV Study Group, Sönnerborg A, Vandamme AM, Theys K, Baele G.

Bioinformatics. 2017 Dec 15;33(24):3993-3995. doi: 10.1093/bioinformatics/btx535.

33.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.

Vinken L, Fransen K, Pineda-Peña AC, Alexiev I, Balotta C, Debaisieux L, Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sonnerborg A, Vancutsem E, Van den Wijngaert S, Van Ranst M, Verhofstede C, Vandamme AM, Lemey P, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.020. doi: 10.1093/ve/vew036.020. eCollection 2017 Mar. No abstract available.

34.

Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort.

Kalu AW, Telele NF, Gebreselasie S, Fekade D, Abdurahman S, Marrone G, Sönnerborg A.

PLoS One. 2017 Aug 25;12(8):e0182384. doi: 10.1371/journal.pone.0182384. eCollection 2017.

35.

Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden.

Neogi U, Siddik AB, Kalaghatgi P, Gisslén M, Bratt G, Marrone G, Sönnerborg A.

Sci Rep. 2017 Jul 25;7(1):6371. doi: 10.1038/s41598-017-06860-2.

36.

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers.

Vesterbacka J, Rivera J, Noyan K, Parera M, Neogi U, Calle M, Paredes R, Sönnerborg A, Noguera-Julian M, Nowak P.

Sci Rep. 2017 Jul 24;7(1):6269. doi: 10.1038/s41598-017-06675-1.

37.

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.

Häggblom A, Santacatterina M, Neogi U, Gisslen M, Hejdeman B, Flamholc L, Sönnerborg A.

PLoS One. 2017 Jul 20;12(7):e0180140. doi: 10.1371/journal.pone.0180140. eCollection 2017.

38.

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.

Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A.

PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017.

39.

A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model.

Brännström J, Sönnerborg A, Svedhem V, Neogi U, Marrone G.

HIV Med. 2017 Oct;18(9):677-684. doi: 10.1111/hiv.12509. Epub 2017 Apr 26.

40.

Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy.

Zhang W, Morshed MM, Noyan K, Russom A, Sönnerborg A, Neogi U.

Sci Rep. 2017 Apr 6;7(1):666. doi: 10.1038/s41598-017-00759-8.

41.

The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges.

Gourlay A, Noori T, Pharris A, Axelsson M, Costagliola D, Cowan S, Croxford S, d'Arminio Monforte A, Del Amo J, Delpech V, Díaz A, Girardi E, Gunsenheimer-Bartmeyer B, Hernando V, Jose S, Leierer G, Nikolopoulos G, Obel N, Op de Coul E, Paraskeva D, Reiss P, Sabin C, Sasse A, Schmid D, Sonnerborg A, Spina A, Suligoi B, Supervie V, Touloumi G, Van Beckhoven D, van Sighem A, Vourli G, Zangerle R, Porter K; European HIV Continuum of Care Working Group.

Clin Infect Dis. 2017 Jun 15;64(12):1644-1656. doi: 10.1093/cid/cix212.

42.

Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance.

van Tienen C, van de Vijver D, Noori T, Sönnerborg A, Boucher C.

Euro Surveill. 2017 Mar 16;22(11). pii: 30483. doi: 10.2807/1560-7917.ES.2017.22.11.30483. No abstract available.

43.

Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study.

Carlander C, Marrone G, Brännström J, Yilmaz A, Elfgren K, Sparén P, Sönnerborg A.

BJOG. 2017 Oct;124(11):1680-1687. doi: 10.1111/1471-0528.14614. Epub 2017 Apr 5.

44.

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals.

Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren HG, Sönnerborg A, Lund O, Reyes-Terán G, Hecht FM, Deeks SG, Betts MR, Buggert M, Karlsson AC.

Sci Rep. 2017 Jan 13;7:40354. doi: 10.1038/srep40354.

45.

Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort.

Kalu AW, Telele NF, Gebreselasie S, Fekade D, Abdurahman S, Marrone G, Sönnerborg A.

BMC Infect Dis. 2017 Jan 6;17(1):37. doi: 10.1186/s12879-016-2163-1.

46.

Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.

Cuong DD, Sönnerborg A, Van Tam V, El-Khatib Z, Santacatterina M, Marrone G, Chuc NT, Diwan V, Thorson A, Le NK, An PN, Larsson M.

BMC Infect Dis. 2016 Dec 16;16(1):759.

47.

Antiretroviral treatment for HIV infection: Swedish recommendations 2016.

Eriksen J, Albert J, Blaxhult A, Carlander C, Flamholc L, Gisslén M, Josephson F, Karlström O, Navér L, Svedhem V, Yilmaz A, Sönnerborg A.

Infect Dis (Lond). 2017 Jan;49(1):1-34. Epub 2016 Nov 2.

PMID:
27804313
48.

Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.

Aralaguppe SG, Winner D, Singh K, Sarafianos SG, Quiñones-Mateu ME, Sönnerborg A, Neogi U.

J Med Virol. 2017 Jan;89(1):106-111. doi: 10.1002/jmv.24610. Epub 2016 Jul 6.

PMID:
27328744
49.

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries.

Esbjörnsson J, Mild M, Audelin A, Fonager J, Skar H, Bruun Jørgensen L, Liitsola K, Björkman P, Bratt G, Gisslén M, Sönnerborg A, Nielsen C; SPREAD/ESAR Programme, Medstrand P, Albert J.

Virus Evol. 2016 Apr 27;2(1):vew010. eCollection 2016 Jan.

50.

Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study.

Brännström J, Svedhem V, Marrone G, Andersson Ö, Azimi F, Blaxhult A, Sönnerborg A.

PLoS One. 2016 Sep 7;11(9):e0162503. doi: 10.1371/journal.pone.0162503. eCollection 2016.

Supplemental Content

Loading ...
Support Center